1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Utility of cfDNA testing for acquired resistance: The Memorial Sloan Kettering experience with plasma EGFR T790M clinical testing
    Meeting Abstract

    Offin, M.; Myers, M.; Josyula, S.; Shen, R.; Borsu, L.; Tsui, D.; Riely, G.; Rudin, C.; Yu, H.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 status with outcomes for immune checkpoint inhibitors in advanced NSCLC patients
    Meeting Abstract

    Mezquita, L.; Park, W.; Arbour, K.; Auclin, E.; Hendriks, L.; Planchard, D.; Saravia, D.; Ponce Aix, S.; Nadal, E.; Audigier-Valette, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Long-term outcomes with first-line nivolumab plus ipilimumab in advanced NSCLC: 3-year follow-up from CheckMate 012
    Meeting Abstract

    Antonia, S.; Gettinger, S.; Borghaei, H.; Goldman, J. W.; Brahmer, J.; Ready, N.; Gerber, D.; Chow, L.; Juergens, R.; Laurie, S.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • CNS activity of ramucirumab in combination with osimertinib in patients with advanced T790M-positive EGFR-mutant NSCLC
    Meeting Abstract

    Paz-Ares, L.; Planchard, D.; Yang, J. C.; Lee, K.; Garrido, P.; Park, K.; Kim, J.; Lee, D. H.; Mao, H.; Chao, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • PARP inhibitor radiosensitization of small cell lung cancer differs by PARP trapping potency
    Meeting Abstract

    Lok, B.; Laird, J.; Ma, J.; De Stanchina, E.; Poirier, J.; Rudin, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB
    Meeting Abstract

    Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • gC1qR expression is independently prognostic for survival benefit following chemotherapy in mesothelioma
    Meeting Abstract

    Li, X.; Eguchi, T.; Aly, R.; Chintala, N.; Tan, K. S.; Messinger, J.; Zauderer, M.; Ghebrehiwet, B.; Adusumilli, P.; Peerschke, E.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and genomic correlates of response to anti-PD1/PD-L1 blockade in non-small cell lung cancers harboring targetable oncogenes
    Meeting Abstract

    Vokes, N.; Jimenez Alguilar, E.; Adeni, A.; Umeton, R.; Sholl, L.; Rizvi, H.; Hellmann, M.; Awad, M.; Van Allen, E.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Long-term safety and clinical activity results from a phase Ib study of erlotinib plus atezolizumab in advanced NSCLC
    Meeting Abstract

    Rudin, C.; Cervantes, A.; Dowlati, A.; Besse, B.; Ma, B.; Costa, D.; Schmid, P.; Heist, R.; Villaflor, V.; Sarkar, I.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save